Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement
UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the pricing of its initial public offering on February 4, 2021 of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $80,000,000 million, before deducting the underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Angion. Angion has also granted the underwriters a 30-day option to purchase from Angion up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Angion’s common sto
Malin Corporation said that its investee company Immunocore has announced the pricing of its initial public offering (IPO) at a price of $26 per share which will result in total gross proceeds of about $258m.
Landos Prices $ 100 Million IPO RTW Venture Fund Limited (the Company ), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by its portfolio company Landos Biopharma, Inc. ( Landos ) on 03 February 2021 of its pricing of a $ 100 million initial public offering ( IPO ) and admission to trade on Nasdaq Global Market under ticker LABP . Landos is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oral therapeutics for patients with autoimmune diseases. The lead asset BT-11 is a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn s disease that targets the LANCL2 pathway.
For the eighth consecutive year,
Eastern Bank, including its Eastern Insurance Group subsidiary, is pleased to announce that it received a score of 100 on the Human Rights Campaign Foundation’s 2021 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ workplace equality. Eastern joins 767 major U.S. businesses that also earned top marks this year, including 48 Massachusetts-based companies.
“Advocating for and defending LGBTQ+ rights has long been important to Eastern,” said Bob Rivers, CEO and Chair of the Board of Eastern Bankshares, Inc. and Eastern Bank. “We are committed to leading with equity and inclusion in our workplace, and to standing up for LGBTQ+ rights in the communities we serve. Thank you to the Human Rights Campaign Foundation for setting a standard for LGBTQ equality, and for recognizing the efforts Eastern and many other Massachusetts-based businesses are advanci
Landos Biopharma Announces Pricing of Initial Public Offering
February 03, 2021 20:13 ET | Source: Landos Biopharma, Inc. Landos Biopharma, Inc. Blacksburg, Virginia, UNITED STATES
BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Landos Biopharma. All of the shares of the common stock are being offered by Landos Biopharma.